EVOGENE WKN: A0Q7UP ISIN: IL0011050551 Kürzel: E3V Forum: Aktien Thema: Hauptdiskussion

Evogene : Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel https://www.marketscreener.com/quote/stock/EVOGENE-LTD-120962472/news/Evogene-Canonic-Announces-Pre-Launch-of-its-First-Generation-Medical-Cannabis-Products-in-Israel-36288842/ Pre-launch of G-nnovation product line to a limited number of patients; Full commercial launch expected in 2022

Evogene Reports Second Quarter 2021 Financial Results https://finance.yahoo.com/news/evogene-reports-second-quarter-2021-110000165.html https://www.earningswhispers.com/epsdetails/evgn Evogene Ltd Ord (EVGN) reported a 2nd Quarter June 2021 loss of $0.15 per share on revenue of $0.1 million. on revenue of $0.3 million. Revenue fell 54.7% compared to the same quarter a year ago.

Evogene : AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate https://www.marketscreener.com/quote/stock/EVOGENE-LTD-56536833/news/Evogene-nbsp-AgPlenus-Announces-Positive-Results-for-a-Herbicide-Resistance-Trait-to-its-Leading-H-35797014/

Evogene Reports First Quarter 2021 Financial Results https://www.marketscreener.com/quote/stock/CORTEVA-INC-59241389/news/Corteva-nbsp-Evogene-Reports-First-Quarter-2021-Financial-Results-Evogene-33357979/ Evogene Q1 EPS $(0.17) Up From $(0.24) YoY, Sales $333.00K Beat $300.00K Estimate https://www.benzinga.com/news/earnings/21/05/21294854/evogene-q1-eps-0-17-up-from-0-24-yoy-sales-333-00k-beat-300-00k-estimate Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.17) per share. This is a 29.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $333.00 thousand which beat the analyst consensus estimate of $300.00 thousand by 11.00 percent. This is a 344.00 percent increase over sales of $75.00 thousand the same period last year.

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma https://www.prnewswire.com/news-releases/biomica-announces-positive-pre-clinical-results-demonstrating-efficacy-of-bmc128-in-melanoma-301267404.html Biomica's live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

Plastomics and Evogene's Ag-Seed division enter a collaborative agreement targeting novel insect control traits for soybean https://www.prnewswire.com/il/news-releases/plastomics-and-evogenes-ag-seed-division-enter-a-collaborative-agreement-targeting-novel-insect-control-traits-for-soybean-301249298.html The parties will test in soybean, Evogene's candidate genes for insect control utilizing Plastomics' novel chloroplast transformation technology  ...

Heftig, wie der Wert hier zerissen wird seit Tagen. Mehr als 50% gefallen. Komplette Übertreibung. Gut gelaufen hin oder her...

Evogene Reports Fourth Quarter and Full Year 2020 Financial Results https://www.prnewswire.com/news-releases/evogene-reports-fourth-quarter-and-full-year-2020-financial-results-301239537.html

Hammer Performance!

🍀

Evogene Provides 2020 Year-End Update for CRISPR-IL Consortium https://finance.yahoo.com/news/evogene-provides-2020-end-crispr-120000314.html

Lavie Bio Provides Product Pipeline Update for 2020 https://www.prnewswire.com/news-releases/lavie-bio-provides-product-pipeline-update-for-2020-301198936.html LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022. ...

👍

löppt

🍀

Wunderschön :)